ClinicalTrials.gg
RecruitingNCT05312268Updated May 9, 2023

Rasburicase Treatment in Chronic Gouty Arthritis

A Phase 4 interventional study of Rasburicase in Chronic Gout, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 4 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Gout with a site in China — 11 open to participants now, 15 under way, 2 of them phase 3. Gout · China.

Planned enrollment
29th of 44
60 · median 93
Started
2022
with 3 others
Phase 4
3 of 49
2 open now
Primary completion
2024-10
later than 2 of 14 live
Registered
22nd of 49
by date

Among the 49 studies in Gout with a site in China, this one is the 29th largest by planned enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2022, is one of 3 in phase 4, reaches primary completion later than 2 of the 14 other live ones, and was the 22nd registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

11 of the 49 studies in Gout with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Gout with a site in China, or all of them as a file.
02

Study summary

The study will establish efficacy and safety of rasburicase in chronic gouty arthritis

Read the detailed description

The study hypothesis is that the proportion of patients who achieved the primary endpoint after 12 weeks of treatment with rasburicase combined with oral urate-lowering therapy is superior to 12 weeks of treatment with oral urate-lowering therapy.

03

Conditions studied

  • Chronic Gout

Browse trials for

Keywords

  • Chronic gouty arthritis
  • Rasburicase
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed, able to understand and comply with the requirements of the study;
  • Male and female patients 18 to 70 years of age;
  • Fulfill the ACR/EULAR 2015 gout classification criteria;
  • Tophi detected by physical examination;
  • Serum urate>300μmol/L (5mg/dl) after one-month maximum dose of urate-lowering therapy (allopurinol 600mg/d or febuxostat 80mg/d in combination with benzbromarone 100mg/d) unless intolerable OR no reduction in size of tophi after serum urate\<300μmol/L (5mg/dl) for six month;

Exclusion criteria

Exclusion Criteria:

  • Pregnant women, lactating women, and men or women who have recently prepared for pregnancy;
  • Abnormal liver function with , ALT, and GGT >3 times ;
  • Blood WBC\<4.0×10\^9/L, and/or \<90g/L, and/or ;\<100×10\^9/L; or other hematologic disorders;
  • \<15 ml/min;
  • Receive following medications: azathioprine, mercaptopurine, cyclosporine, pyrazinamide, ethambutol and sulfamethoxazole
  • Psychiatric disorders, history of alcoholism, drug or other substance abuse
  • Immunodeficiency diseases, uncontrolled infection, etc;
  • Sericosis, glucose-6-phosphate dehydrogenase activity deficiency
  • Allergy to biological agents and chronic active urticaria.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Group A

    Rasburicase treatment at week 1, 4 and 8 with stable dose oral urate-lowering therapy for 24 weeks.

    Drug: Rasburicase

  • Other
    Group B

    Rasburicase treatment at week 12, 16 and 20 with stable dose oral urate-lowering therapy for 24 weeks.

    Drug: Rasburicase

Interventions

  • Rasburicase 1.5 mg/day for 3 consecutive days at scheduled times.

06

What researchers measure

Primary outcomes

  1. Monosodium urate crystal volume change evaluated by dual energy CT

    Dual energy CT at baseline, week 12 and week 24

    Time frame: Baseline to week 12 and week 12 to week 24

Secondary outcomes

  1. Tophus volume change evaluated by physical examination

    Time frame: Baseline to week 12 and week 12 to week 24

  2. The percentage of patients who have at least one tophi disappeared

    Time frame: Baseline to week 12 and week 12 to week 24

  3. The percentage of patients who had achieved serum urate concentrations less than 300 μmol/L (5mg/dl) after 3 months of rasburicase treatment

    Time frame: Baseline to week 12 and week 12 to week 24

  4. Number of gout flare

    Time frame: Baseline to week 12 and week 12 to week 24

  5. Change of patient global assessment

    The patient global assessment is given as a single question, scored from 0-10, with higher numbers representing worse perceived disease activity or overall health.

    Time frame: Baseline to week 12 and week 12 to week 24

  6. Change of physician global assessment

    The physician global assessment is given as a single question, scored from 0-10, with higher numbers representing worse perceived disease activity or overall health.

    Time frame: Baseline to week 12 and week 12 to week 24

  7. Change of Visual Analog Scale (VAS) for Pain in gout flare

    Visual Analog for Pain consists of a horizontal line, usually 100mm in length. The left end of the line signifies no pain while the right end signifies the worst possible pain.

    Time frame: Baseline to week 12 and week 12 to week 24

  8. Change of global functional status

    The criteria are as follows: class I = able to perform usual activities of daily living (self-care, vocational, and avocational); class II = able to perform usual self-care and vocational activities, but limited in avocational activities; class III = able to perform usual self-care activities but limited in vocational and avocational activities; class IV = limited in ability to perform usual self-care, vocational, and avocational activities.

    Time frame: Baseline to week 12 and week 12 to week 24

  9. Change of Short Form 12 health survey score

    Time frame: Baseline to week 12 and week 12 to week 24

  10. Change of Tophus Impact Questionnaire (TIQ)-20 score

    Time frame: Baseline to week 12 and week 12 to week 24

  11. Adverse event

    Time frame: Baseline to week 12 and week 12 to week 24

  12. Severe adverse event

    Time frame: Baseline to week 12 and week 12 to week 24

  13. Number of patients who have positive anti-rasburicase antibodies

    Time frame: Baseline to week 12 and week 12 to week 24

07

Study locations

1 of 4 sites recruiting
  • Shunde Hospital of Southern Medical University
    Foshan, Guangdong, China
    Not yet recruiting
    • Bin Yang, M.D.&Ph.D · Contact2075722318000
    • Bin Liu, M.D.&Ph.D · Principal investigator
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510120, China
    Recruiting
  • Panyu Central Hospital
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Haijun Liu, M.D.&Ph.D · Contactkayjun0753@126.com · 862034858888
    • Haijun Liu, M.D.&Ph.D · Principal investigator
  • Shenshan Medical Center
    Shanwei, Guangdong 516600, China
    Not yet recruiting
    • Yingqian Mo, M.D.&Ph.D · Contactmoyingq@mail.sysu.edu.cn · 866603863000
    • Yingqian Mo, M.D.&Ph.D · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Oct 2024, 28 months after the start.

Of 19 phase 4 interventional studies under Gout, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 28 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2022
First posted
Apr 5, 2022
StartActual
Jun 15, 2022
Primary completionEst.
Oct 15, 2024
CompletionEst.
Apr 15, 2025
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05312268
Responsible party
Sponsor
First posted
Apr 5, 2022
Start date
Jun 15, 2022
Primary completion
Oct 15, 2024 (estimated)
Completion
Apr 15, 2025 (estimated)
Last update
May 9, 2023

Study contacts

Qianhua Li, M.D.&Ph.D
Contact
liqianhua@mail.sysu.edu.cn
862081332572
Qianhua Li, M.D.&Ph.D
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rasburicase

Start the discussion